Home » Newsletters » BioWorld Science

BioWorld Science

Oct. 30, 2001

View Archived Issues

Progress continues as planned in Tularik's clinical development programs

Fabrazyme available to Fabry's disease patients in several E.U. countries

Metvix: first PDT for skin cancer introduced in Sweden

PS-341 dose-dependently reduces serum IL-6 and PSA levels in prostate cancer patients

Phase II trials on sleep extended by Theratechnologies

Successful completion of oxymorphone pain management clinical trial

Progenics and Formatech collaborate on HIV drug PRO-542

Avastin reaches prespecified endpoint early in phase II trial

Novel KDR tyrosine kinase inhibitor well tolerated in ongoing phase I trials

Genta's antisense therapy targeting Bcl-2 combined with docetaxel for prostate cancer

Ligand highlights Q3 developments

Multitargeted antifolate has promising activity, good tolerability in pleural mesothelioma

Avant continues to advance products into later stages of clinical development

Less phototoxic photosensitizer developed at Roswell Park Cancer Institute

Investigational nonstimulant treatment for ADHD discussed extensively in Istanbul

First regulatory approval obtained for Viread

Shire's once-daily Adderall XR launched in U.S. for treatment of ADHD

Oculex commences phase II trial of Posurdex for PME

New findings on anthrax toxin may lead to development of antitoxin compounds

Estrogen replacement therapy does not reduce death after stroke

Carboxamide-based HCV NS3 protease inhibitors disclosed by DuPont

Henry Ford Hospital develops double suicide gene therapy for prostate cancer

Potent and selective PDE4 inhibitors claimed by Sanofi-Synthelabo in patent literature

New CDK inhibitors from Aventis particularly useful in Alzheimer's disease

Chemokine receptor modulators and their uses described in recent patent

Scios identifies new p38alpha kinase inhibitors

Pentapeptide LHRH antagonists in the Abbott pipeline

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for March 10, 2026.
Cas and effect: Merck’s phase III ripples HIF-2α space
BioWorld
Oddsmakers wasted no time figuring the market chances after Merck & Co. Inc. rolled out data from the phase III Litespark-011 study testing its oral...
Brain’s hidden tau-clearing pathway uncovered
BioWorld Science
Researchers at INSERM and collaborators have identified hypothalamic tanycytes as mediators of tau clearance and shown that their structural and genetic...
News in brief
BioWorld Asia
BioWorld Asia briefs for March 10, 2026
MSD synthesizes α-synuclein PET agents
BioWorld Science
Merck Sharp & Dohme LLC (MSD) has prepared and tested new positron emission tomography (PET) agents for binding and imaging α-synuclein (SNCA) for the diagnosis...